1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Virology
  4. Volume 3, 2016
  5. Article

Annual Review of Virology

Volume 3, 2016

Epidemiology and Management of the 2013–16 West African Ebola Outbreak

Abstract

The 2013–16 West African Ebola outbreak is the largest, most geographically dispersed, and deadliest on record, with 28,616 suspected cases and 11,310 deaths recorded to date in Guinea, Liberia, and Sierra Leone. We provide a review of the epidemiology and management of the 2013–16 Ebola outbreak in West Africa aimed at stimulating reflection on lessons learned that may improve the response to the next international health crisis caused by a pathogen that emerges in a region of the world with a severely limited health care infrastructure. Surveillance efforts employing rapid and effective point-of-care diagnostics designed for environments that lack advanced laboratory infrastructure will greatly aid in early detection and containment efforts during future outbreaks. Introduction of effective therapeutics and vaccines against Ebola into the public health system and the biodefense armamentarium is of the highest priority if future outbreaks are to be adequately managed and contained in a timely manner.

Keyword(s): Ebola virus, epidemiology, filoviruses, outbreak management, point-of-care testing, viral diagnostics, viral genetics, viral therapeutics, viral vaccines
Loading

Article metrics loading...

/content/journals/10.1146/annurev-virology-110615-040056
2016-09-29
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/virology/3/1/annurev-virology-110615-040056.html?itemId=/content/journals/10.1146/annurev-virology-110615-040056&mimeType=html&fmt=ahah

Literature Cited

  1. Amblard J, Obiang P, Edzang S, Prehaud C, Bouloy M, Guenno BLE. 1.  1997. Identification of the Ebola virus in Gabon in 1994. Lancet 349:181–82 [Google Scholar]
  2. Georges AJ, Leroy EM, Renaut AA, Benissan CT, Nabias RJ. 2.  et al. 1999. Ebola hemorrhagic fever outbreaks in Gabon, 1994–1997: epidemiologic and health control issues. J. Infect. Dis. 179:S65–75 [Google Scholar]
  3. Grard G, Biek R, Tamfum JJ, Fair J, Wolfe N. 3.  et al. 2011. Emergence of divergent Zaire Ebola virus strains in Democratic Republic of the Congo in 2007 and 2008. J. Infect. Dis. 204:S776–84 [Google Scholar]
  4. Kratz T, Roddy P, Tshomba Oloma A, Jeffs B, Pou Ciruelo D. 4.  et al. 2015. Ebola virus disease outbreak in Isiro, Democratic Republic of the Congo, 2012: signs and symptoms, management and outcomes. PLOS ONE 10:e0129333 [Google Scholar]
  5. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S. 5.  et al. 2008. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLOS Pathog. 4:e1000212 [Google Scholar]
  6. Muyembe-Tamfum JJ, Kipasa M, Kiyungu C, Coleblunders R. 6.  1999. Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. J. Infect. Dis. 179:S259–62 [Google Scholar]
  7. Muyembe-Tamfum JJ, Mulangu S, Masumu J, Kayembe JM, Kemp A, Paweska JT. 7.  2012. Ebola virus outbreaks in Africa: past and present. Onderstepoort J. Vet. Res. 79:451 [Google Scholar]
  8. 8. WHO 2016. Ebola situation report: January 20, 2016 WHO Geneva, Switz.: http://apps.who.int/ebola/current-situation/>ebola-situation-report-20-january-2016
  9. Ladner JT, Wiley MR, Mate S, Dudas G, Prieto K. 9.  et al. 2015. Evolution and spread of Ebola virus in Liberia, 2014–2015. Cell Host Microbe 18:659–69 [Google Scholar]
  10. Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ. 10.  et al. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369–72EBOV sequencing from 78 Sierra Leonean patients, revealing divergence from Central Africa and transmission from Guinea. [Google Scholar]
  11. Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN. 11.  2014. Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerg. Infect. Dis. 20:1176–82 [Google Scholar]
  12. Boisen ML, Schieffelin JS, Goba A, Oottamasathien D, Jones AB. 12.  et al. 2015. Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral. Immunol. 28:19–31 [Google Scholar]
  13. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L. 13.  et al. 2014. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371:1418–25Emergence of EVD cases in Guinea and contact tracing to index case. [Google Scholar]
  14. Althaus CL, Low N, Musa EO, Shuaib F, Gsteiger S. 14.  2015. Ebola virus disease outbreak in Nigeria: transmission dynamics and rapid control. Epidemics 11:80–84 [Google Scholar]
  15. Musa EO, Adedire E, Adeoye O, Adewuyi P, Waziri N. 15.  et al. 2015. Epidemiological profile of the Ebola virus disease outbreak in Nigeria, July–September 2014. Pan. Afr. Med. J. 21:331 [Google Scholar]
  16. Shuaib F, Gunnala R, Musa EO, Mahoney FJ, Oguntimehin O. 16.  et al. 2014. Ebola virus disease outbreak: Nigeria, July–September 2014. Morb. Mortal. Wkly. Rep. 63:867–72 [Google Scholar]
  17. Flynn D. 17.  2014. Guinean student is first case of Ebola confirmed in Senegal. Reuters Aug. 29. http://www.reuters.com/article/us-health-ebola-senegal-idUSKBN0GT1CD20140829
  18. Hoenen T, Safronetz D, Groseth A, Wollenberg KR, Koita OA. 18.  et al. 2015. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 348:117–19 [Google Scholar]
  19. Lopaz MA, Amela C, Ordobas M, Dominguez-Berjon MF, Alvarez C. 19.  et al. 2015. First secondary case of Ebola outside Africa: epidemiological characteristics and contact monitoring, Spain, September to November 2014. Eurosurveillance 20:21003 [Google Scholar]
  20. 20. CDC. 2016. 2014 Ebola outbreak in West Africa: outbreak distribution map CDC Atlanta, GA: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/distribution-map.html
  21. 21. CDC. 2014. Cases of Ebola diagnosed in the United StatesCDC Atlanta, GA: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/united-states-imported-case.html
  22. Feldmann H, Geisbert TW. 22.  2011. Ebola haemorrhagic fever. Lancet 377:849–62 [Google Scholar]
  23. Ito H, Watanabe S, Takada A, Kawaoka Y. 23.  2001. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75:1576–80 [Google Scholar]
  24. Modrof J, Muhlberger E, Klenk HD, Becker S. 24.  2002. Phosphorylation of VP30 impairs Ebola virus transcription. J. Biol. Chem. 277:33099–104 [Google Scholar]
  25. Trunschke M, Conrad D, Enterlein S, Olejnik J, Brauburger K, Muhlberger E. 25.  2013. The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology 441:135–45 [Google Scholar]
  26. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. 26.  2000. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. PNAS 97:13871–76 [Google Scholar]
  27. Han Z, Boshra H, Sunyer JO, Zwiers SH, Paragas J, Harty RN. 27.  2003. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J. Virol. 77:1793–800 [Google Scholar]
  28. 28. CDC. 2009. Arboviruses and related zoonotic viruses. Biosafety in Microbiological and Biomedical Laboratories LCW Chosewood, E Deborah 233–67 Atlanta: CDC [Google Scholar]
  29. Olejnik J, Ryabchikova E, Corley RB, Muhlberger E. 29.  2011. Intracellular events and cell fate in filovirus infection. Viruses 3:1501–31 [Google Scholar]
  30. Hunt CL, Lennemann NJ, Maury W. 30.  2012. Filovirus entry: a novelty in the viral fusion world. Viruses 4:258–75 [Google Scholar]
  31. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. 31.  2006. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80:4174–78 [Google Scholar]
  32. Kindrachuk J, Wahl-Jensen V, Safronetz D, Trost B, Hoenen T. 32.  et al. 2014. Ebola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes. J. Virol. 88:9877–92 [Google Scholar]
  33. Harrison SC. 33.  2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15:690–98 [Google Scholar]
  34. White JM, Delos SE, Brecher M, Schornberg K. 34.  2008. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 43:189–219 [Google Scholar]
  35. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G. 35.  et al. 2003. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188:1630–38 [Google Scholar]
  36. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P. 36.  2002. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76:2518–28 [Google Scholar]
  37. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y. 37.  2000. Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278:20–26 [Google Scholar]
  38. Takada A, Kawaoka Y. 38.  2001. The pathogenesis of Ebola hemorrhagic fever. Trends Microbiol 9:506–11 [Google Scholar]
  39. Harcourt BH, Sanchez A, Offermann MK. 39.  1998. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology 252:179–88 [Google Scholar]
  40. Noda T, Ebihara H, Muramoto Y, Fujii K, Takada A. 40.  et al. 2006. Assembly and budding of Ebolavirus. PLOS Pathog 2:e99 [Google Scholar]
  41. Basler CF, Amarasinghe GK. 41.  2009. Evasion of interferon responses by Ebola and Marburg viruses. J. Interferon Cytokine Res. 29:511–20 [Google Scholar]
  42. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. 42.  1987. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155:456–64 [Google Scholar]
  43. Andersen KG, Shapiro BJ, Matranga CB, Sealfon R, Lin AE. 43.  et al. 2015. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162:738–50 [Google Scholar]
  44. Shaffer JG, Grant DS, Schieffelin JS, Boisen ML, Goba A. 44.  et al. 2014. Lassa fever in post-conflict Sierra Leone. PLOS Negl. Trop. Dis. 8:e2748 [Google Scholar]
  45. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK. 45.  et al. 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N. Engl. J. Med. 371:2092–100Clinical records of EVD patients, showing gastrointestinal manifestations as the most common symptom from EBOV infection. [Google Scholar]
  46. Hunt L, Knott V. 46.  2015. Serious and common sequelae after Ebola virus infection. Lancet Infect. Dis. 16270–71
  47. Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V. 47.  et al. 2015. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect. Dis. 15:1292–99 [Google Scholar]
  48. Yun NE, Walker DH. 48.  2012. Pathogenesis of Lassa fever. Viruses 4:2031–48 [Google Scholar]
  49. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. 49.  2014. Ebola virus disease in West Africa—clinical manifestations and management. N. Engl. J. Med. 371:2054–57 [Google Scholar]
  50. Jaax N, Jahrling PB, Geisbert TW, Geisbert JB, Steele K. 50.  et al. 1995. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346:1669–71 [Google Scholar]
  51. Feldmann F, Feldmann H. 51.  2013. Ebola: facing a new transboundary animal disease?. Dev. Biol. 135:201–9 [Google Scholar]
  52. Wong S, Lau S, Woo P, Yuen KY. 52.  2007. Bats as a continuing source of emerging infections in humans. Rev. Med. Virol. 17:67–91 [Google Scholar]
  53. Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB. 53.  1985. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J. Pathol. 147:199–203 [Google Scholar]
  54. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS. 54.  et al. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques. Am. J. Pathol. 163:2347–70 [Google Scholar]
  55. Larsen T, Stevens EL, Davis KJ, Geisbert JB, Daddario-DiCaprio KM. 55.  et al. 2007. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J. Infect. Dis. 196:S323–28 [Google Scholar]
  56. Emond RTD, Evans B, Bowen ETW, Lloyd G. 56.  1977. A case of Ebola virus infection. BMJ 2:541–44 [Google Scholar]
  57. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ. 57.  et al. 1999. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J. Infect. Dis. 179:S28–35 [Google Scholar]
  58. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A. 58.  et al. 1999. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179:S170–76 [Google Scholar]
  59. Beer B, Kurth R, Bukreyev A. 59.  1999. Characteristics of Filoviridae: Marburg and Ebola virus. Naturwissenschaften 86:8–17 [Google Scholar]
  60. 60. WHO. 1978. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull. World Health Organ. 56:247–70 [Google Scholar]
  61. 61. WHO. 1978. Ebola haemorrhagic fever in Zaire, 1976. Report of an International Commission. Bull. World Health Organ. 56:271–93 [Google Scholar]
  62. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML. 62.  et al. 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179:S177–87 [Google Scholar]
  63. Lamunu M, Lutwama JJ, Kamugisha J, Opio A, Nambooze J. 63.  et al. 2004. Containing a haemorrhagic fever epidemic: the Ebola experience in Uganda (October 2000–January 2001). Int. J. Infect. Dis. 8:27–37 [Google Scholar]
  64. Branco LM, Boisen ML, Andersen KG, Grove JN, Moses LM. 64.  et al. 2011. Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Virol. J. 8:404 [Google Scholar]
  65. 65. WHO. 2014. Sierra Leone: how Kailahun district kicked Ebola out WHO Geneva, Switz.:
  66. Wauquier N, Bangura J, Moses L, Humarr Khan S, Coomber M. 66.  et al. 2015. Understanding the emergence of Ebola virus disease in Sierra Leone: stalking the virus in the threatening wake of emergence. PLOS Curr. 7: doi: 10.1371/currents.outbreaks.9a6530ab7bb9096b34143230ab01cdef [Google Scholar]
  67. Wells C, Yamin D, Ndeffo-Mbah ML, Wenzel N, Gaffney SG. 67.  et al. 2015. Harnessing case isolation and ring vaccination to control Ebola. PLOS Negl. Trop. Dis. 9:e0003794 [Google Scholar]
  68. 68. Ebola ça Suffit Ring Vaccination Trial Consort. 2015. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ 351:h3740 [Google Scholar]
  69. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ. 69.  et al. 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857–66Promising results for rVSV-ZEBOV vaccine in vaccinated groups versus delayed-vaccination groups in Guinea. [Google Scholar]
  70. Kucharski AJ, Eggo RM, Watson CH, Camacho A, Funk S, Edmunds WJ. 70.  2016. Effectiveness of ring vaccination as control strategy for Ebola virus disease. Emerg. Infect. Dis. 22:105–8 [Google Scholar]
  71. Marzi A, Feldmann F, Hanley PW, Scott DP, Gunther S, Feldmann H. 71.  2015. Delayed disease progression in cynomolgus macaques infected with Ebola virus Makona strain. Emerg. Infect. Dis. 21:1777–83 [Google Scholar]
  72. Qiu X, Audet J, Lv M, He S, Wong G. 72.  et al. 2016. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci. Transl. Med. 8:329ra33 [Google Scholar]
  73. Simon-Loriere E, Faye O, Faye O, Koivogui L, Magassouba N. 73.  et al. 2015. Distinct lineages of Ebola virus in Guinea during the 2014 West African epidemic. Nature 524:102–4 [Google Scholar]
  74. Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G. 74.  et al. 2015. Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa. Nature 524:97–101 [Google Scholar]
  75. Tong YG, Shi WF, Liu D, Qian J, Liang L. 75.  et al. 2015. Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. Nature 524:93–96 [Google Scholar]
  76. Arwady MA, Bawo L, Hunter JC, Massaquoi M, Matanock A. 76.  et al. 2015. Evolution of Ebola virus disease from exotic infection to global health priority, Liberia, mid-2014. Emerg. Infect. Dis. 21:578–84 [Google Scholar]
  77. Park DJ, Dudas G, Wohl S, Goba A, Whitmer SL. 77.  et al. 2015. Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone. Cell 161:1516–26 [Google Scholar]
  78. Jeffs B, Roddy P, Weatherill D, de la Rosa O, Dorion C. 78.  et al. 2007. The Médecins Sans Frontières intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. I. Lessons learned in the hospital. J. Infect. Dis. 196:S154–61 [Google Scholar]
  79. Grolla A, Jones SM, Fernando L, Strong JE, Stroher U. 79.  et al. 2011. The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg outbreak in Angola. PLOS Negl. Trop. Dis. 5:e1183 [Google Scholar]
  80. Grove JN, Branco LM, Boisen ML, Muncy IJ, Henderson LA. 80.  et al. 2011. Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol. J. 8:314 [Google Scholar]
  81. Niikura M, Ikegami T, Saijo M, Kurane I, Miranda ME, Morikawa S. 81.  2001. Detection of Ebola viral antigen by enzyme-linked immunosorbent assay using a novel monoclonal antibody to nucleoprotein. J. Clin. Microbiol. 39:3267–71 [Google Scholar]
  82. Nakayama E, Yokoyama A, Miyamoto H, Igarashi M, Kishida N. 82.  et al. 2010. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin. Vaccine Immunol. 17:1723–28 [Google Scholar]
  83. Duan D, Fan K, Zhang D, Tan S, Liang M. 83.  et al. 2015. Nanozyme-strip for rapid local diagnosis of Ebola. Biosens. Bioelectron. 74:134–41 [Google Scholar]
  84. Fukushi S, Tani H, Yoshikawa T, Saijo M, Morikawa S. 84.  2012. Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers. Viruses 4:2097–114 [Google Scholar]
  85. Kaushik A, Tiwari S, Dev Jayant R, Marty A, Nair M. 85.  2015. Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosens. Bioelectron. 75:254–72 [Google Scholar]
  86. Walker NF, Brown CS, Youkee D, Baker P, Williams N. 86.  et al. 2015. Evaluation of a point-of-care blood test for identification of Ebola virus disease at Ebola holding units, Western Area, Sierra Leone, January to February 2015. Eurosurveillance 20:21073 [Google Scholar]
  87. Stamm LV. 87.  2015. Ebola virus disease: rapid diagnosis and timely case reporting are critical to the early response for outbreak control. Am. J. Trop. Med. Hyg. 93:438–40 [Google Scholar]
  88. Boisen ML, Cross RW, Hartnett JN, Goba A, Momoh M. 88.  et al. 2016. Field validation of the ReEBOV® Antigen Rapid Test for point-of-care diagnosis of Ebola virus infection. J. Infect. Dis. In press [Google Scholar]
  89. Cross RW, Boisen ML, Millett MM, Nelson DS, Oottamasathien D. 89.  et al. 2016. Analytical validation of the ReEBOV® Antigen Rapid Test for point-of-care diagnosis of Ebola virus infection. J. Infect. Dis. In press [Google Scholar]
  90. 90. WHO. 2015. WHO emergency use assessment and listing for Ebola virus disease IVDs: public report. WHO Geneva, Switz.:
  91. Vogt F, Fitzpatrick G, Patten G, van den Bergh R, Stinson K. 91.  et al. 2015. Assessment of the MSF triage system, separating patients into different wards pending Ebola virus laboratory confirmation, Kailahun, Sierra Leone, July to September 2014. Eurosurveillance 20:30097Design of Ebola management center and evaluation of EVD patient triage system. [Google Scholar]
  92. Fitzpatrick G, Vogt F, Moi Gbabai OB, Decroo T, Keane M. 92.  et al. 2015. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Médecins Sans Frontières Ebola case management centre, Kailahun, Sierra Leone, June–October 2014. J. Infect. Dis. 212:1752–58 [Google Scholar]
  93. Nouvellet P, Garske T, Mills HL, Nedjati-Gilani G, Hinsley W. 93.  et al. 2015. The role of rapid diagnostics in managing Ebola epidemics. Nature 528:S109–16 [Google Scholar]
  94. Hartnett JN, Boisen ML, Oottamasathien D, Jones AB, Millett MM. 94.  et al. 2015. Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virol 10:559–84 [Google Scholar]
  95. Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A. 95.  et al. 2012. Viral hemorrhagic fevers: advancing the level of treatment. BMC Med. 10:31 [Google Scholar]
  96. Cohen J, Enserink M. 96.  2016. As Ebola epidemic draws to a close, a thin scientific harvest. Science 351:12–13 [Google Scholar]
  97. Jahrling PB, Frame JD, Rhoderick JB, Monson MH. 97.  1985. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans. R. Soc. Trop. Med. Hyg. 79:380–84 [Google Scholar]
  98. Jahrling PB, Peters CJ, Stephen EL. 98.  1984. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infect. Dis. 149:420–27 [Google Scholar]
  99. McCormick JB. 99.  1986. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med. Microbiol. Immunol. 175:153–55 [Google Scholar]
  100. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB. 100.  et al. 1986. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314:20–26 [Google Scholar]
  101. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P. 101.  et al. 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374:33–42 [Google Scholar]
  102. Florescu DF, Kalil AC, Hewlett AL, Schuh AJ, Stroher U. 102.  et al. 2015. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin. Infect. Dis. 61:969–73 [Google Scholar]
  103. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ. 103.  et al. 2015. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 61:496–502 [Google Scholar]
  104. Qiu X, Wong G, Audet J, Bello A, Fernando L. 104.  et al. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53 [Google Scholar]
  105. Cohen J, Enserink M. 105.  2015. Special report: Ebola's thin harvest. Science. doi: 10.1126/science.aae0164
  106. Thi EP, Mire CE, Ursic-Bedoya R, Geisbert JB, Lee AC. 106.  et al. 2014. Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med. 6:250ra116 [Google Scholar]
  107. Ursic-Bedoya R, Mire CE, Robbins M, Geisbert JB, Judge A. 107.  et al. 2014. Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J. Infect. Dis. 209:562–70 [Google Scholar]
  108. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN. 108.  et al. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375:1896–905 [Google Scholar]
  109. Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J. 109.  et al. 2016. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin. Pharmacokinet. In press [Google Scholar]
  110. 110. Arbutus Biopharma Corp. 2015. Safety, tolerability and pharmacokinetic first in human (FIH) study for intravenous (IV) TKM-100802 Clin. Trial Identif. NCT02041715 Nat. Libr. Med. Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT02041715
  111. Madelain V, Oestereich L, Graw F, Nguyen TH, de Lamballerie X. 111.  et al. 2015. Ebola virus dynamics in mice treated with favipiravir. Antivir. Res. 123:70–77 [Google Scholar]
  112. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. 112.  2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105:17–21 [Google Scholar]
  113. Qiu X, Wong G, Fernando L, Audet J, Bello A. 113.  et al. 2013. mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci. Transl. Med. 5:207ra143 [Google Scholar]
  114. Qiu X, Wong G, Fernando L, Ennis J, Turner JD. 114.  et al. 2013. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. J. Virol. 87:7754–57 [Google Scholar]
  115. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A. 115.  et al. 2013. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis. 208:310–18 [Google Scholar]
  116. Clegg CS, Lloyd G. 116.  1987. Vaccina recombinant expressing Lassa-virus internal nucleocapsid protein protects guinea pigs against Lassa fever. Lancet 330:186–88 [Google Scholar]
  117. Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Bavari S. 117.  et al. 2015. Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection. PLOS ONE 10:e0118345 [Google Scholar]
  118. Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Dye JM. 118.  et al. 2014. Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the Toll-like receptor and interferon signaling pathways. J. Interferon Cytokine Res. 34:79–89 [Google Scholar]
  119. Zhang L, Lu J, Chen Y, Shi F, Yu H. 119.  et al. 2015. Characterization of humoral responses induced by an H7N9 influenza virus-like particle vaccine in BALB/c mice. Viruses 7:4369–84 [Google Scholar]
  120. Warfield KL, Dye JM, Wells JB, Unfer RC, Holtsberg FW. 120.  et al. 2015. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLOS ONE 10:e0118881 [Google Scholar]
  121. Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D. 121.  et al. 2007. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J. Infect. Dis. 196:S421–29 [Google Scholar]
  122. Rodrigues AF, Soares HR, Guerreiro MR, Alves PM, Coroadinha AS. 122.  2015. Viral vaccines and their manufacturing cell substrates: new trends and designs in modern vaccinology. Biotechnol. J. 10:1329–44 [Google Scholar]
  123. Poteet E, Lewis P, Li F, Zhang S, Gu J. 123.  et al. 2015. A novel prime and boost regimen of HIV virus-like particles with TLR4 adjuvant MPLA induces Th1 oriented immune responses against HIV. PLOS ONE 10:e0136862 [Google Scholar]
  124. Beljanski V, Chiang C, Kirchenbaum GA, Olagnier D, Bloom CE. 124.  et al. 2015. Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J. Virol. 89:10612–24 [Google Scholar]
  125. Christie A, Davies-Wayne GJ, Cordier-Lassalle T, Blackley DJ, Laney AS. 125.  et al. 2015. Possible sexual transmission of Ebola virus—Liberia, 2015. Morb. Mortal. Wkly. Rep. 64:479–81 [Google Scholar]
  126. Arden K, Johnson G, Knibbs L, Mackay I. 126.  2014. Ebola virus may be spread by droplets, but not by an airborne route: what that means. Virology Down Under Blog Aug. 15. http://virologydownunder.blogspot.com/2014/08/ebola-virus-may-be-spread-by-droplets.html
  127. Mayaux P, Pekel JF, Desclee B, Donnay F, Lupi A. 127.  et al. 2013. State and evolution of the African rainforests between 1990 and 2010. Philos. Trans. R. Soc. B 368:20120300 [Google Scholar]
/content/journals/10.1146/annurev-virology-110615-040056
Loading
Epidemiology and Management of the 2013–16 West African Ebola Outbreak
Annual Review of Virology 3, 147 (2016); https://doi.org/10.1146/annurev-virology-110615-040056
/content/journals/10.1146/annurev-virology-110615-040056
/content/journals/10.1146/annurev-virology-110615-040056
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error